Grupo Auguri has acquired a controlling interest in Clínica Las Condes S.A.
Grupo Auguri has acquired a controlling interest in Clínica Las Condes S.A.
Grupo Auguri is a Chilean family office linked to the Karlezi Solari family, which have investments in multiple companies from various industries throughout the country and abroad.
Based in Santiago, Clínica Las Condes is one of the largest private hospitals in Chile. The company initiated its operations in 1982 with a focus on high complexity medicine. Its services include inpatient medical, surgical intensive care units, intermediate, adult, pediatric, neonatal, surgical wards, post-recovery operative, clinical laboratories, radiology, CT magnetic resonance imaging, radiation therapy, PET-CT, nuclear medicine, ultrasound, dialysis and other services that include outpatient procedures.
Oaklins’ team in Chile acted as financial advisor to Grupo Auguri in this transaction.
Contáctese con el equipo de la transacción
Transacciones relacionadas
Instituto Sanitas and Chemopharma have been acquired by Laboratorios Saval
Instituto Sanitas and Chemopharma, leading pharmaceutical laboratories in Chile, have been acquired by Laboratorios Saval S.A., a prominent pharmaceutical company based in Chile with a regional presence across Latin America. The transaction strengthens Laboratorios Saval’s growth strategy and supports its expansion in the affordable medicines segment.
Aprenda másRare Patient Voice has been acquired by Konovo
Rare Patient Voice has been acquired by Konovo, a technology-first healthcare intelligence company backed by Fraser Healthcare Partners.
Aprenda másLindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.
Aprenda más